Z-Medica said it named Stephen Fanning, the former CEO of Solta Medical, to be its new chief executive.
Wallingford, Conn.-based Z-Medica is developing blood clotting technologies it calls QuikClot.
"QuikClot products have been adopted by the U.S. military and are gaining awareness in a variety of healthcare and emergency response settings. We have the ability to increase our growth rate by applying the company’s unique technology to address unmet medical needs in a significant number of major markets including hospitals, military, first responders, law enforcement, institutional settings and consumer retail outlets. In addition, our leadership in blood clotting technology creates the opportunity to expand our platform with our current and potential customer base. I am excited about the Z-Medica opportunity and working with the entire team to capitalize on our potential," Fanning said in prepared remarks.
Fanning left Solta Medical in September 2013, a few months before Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) agreed to pay $250 million for the aesthetic device maker. That deal closed in January.
Stryker plans finance succession
Stryker (NYSE:SYK) said its longtime legal chief, Curtis Hall, is moving to a part-time role as senior legal counsel in preparation for Michael Hutchinson to take over as general counsel. Hall became Stryker’s 1st general counsel in 1994.
Read more
Exactech kicks founder & CEO Bill Petty upstairs, taps son for corner office
Exactech (NSDQ:EXAC)
said it kicked co-founder & CEO Dr. Bill Petty upstairs, naming him executive chairman and tapping son David Petty for the corner office.
Read more
Pixium Vision’s new CEO is Boston Scientific vet Ishaque
Pixium Vision said it named 17-year Boston Scientific (NYSE:BSX)
veteran Khalid Ishaque as its new CEO. Ishaque was most recently general manager of Boston’s neuromodulation International business.
Read more
Covidien vet to lead Arch Therapeutics’ R&D arm
Arch Therapeutics (OTC:ARTH) said it named Chirag Shah vice president of R&D, engineering & quality systems. Shah spent a decade at Covidien (NYSE:COV), most recently as senior director of the biomaterials research & development center of excellence in vascular therapies. Arch also said it tapped Peter LaCrosse as its new chief of staff.
Read more
